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Abstract: Pregnancy is a period in a woman’s life associated with an increased risk of developing
lower extremity chronic venous disease (CVD). Pregnancy-associated CVD is associated with changes
in placental villi. We investigated angiogenesis and lymphangiogenesis in the placental villi of
women with CVD during pregnancy compared with healthy controls with no history of CVD (HC).
An observational, analytical, and prospective cohort study was conducted on 114 women in their
third trimester of pregnancy (32 weeks). Sixty-two participants were clinically diagnosed with CVD.
In parallel, 52 controls with no history of CVD (HC) were studied. Gene and protein expression
of CD31, podoplanin (D2-40), Flt-1, and placental growth factor (PIGF) was analysed by real-time
polymerase chain reaction (RT-qPCR) and immunohistochemistry. CD31 and D2-40 gene expression
was significantly greater in the placental villi of women with CVD, as were the numbers of vessels
positive for CD31 and D2-40. Significantly higher gene and protein expression of Flt-1 and PIGF was
observed in the placental villi of women with CVD. Histological analysis showed more placental villi
with periodic acid of Schiff (PAS)-positive material in women with CVD. Our results show a connection
between pregnancy-associated CVD and leading to higher proangiogenic and lymphangiogenic
activity in placental villi.
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1. Introduction
Chronic venous disease (CVD) refers to various anomalies commonly affecting the lower
extremities, in which venous return is abnormal, and varicose veins are the most important clinical
manifestation [1]. Pregnancy is associated with an increased risk of developing chronic venous
disorder [2,3]. Risk factors associated with venous disorder during pregnancy include genetic
factors and family history, occupation, and the number of pregnancies or the interval between
pregnancies [4]. Several haemodynamic changes occur in pregnant women, including greater
vasodilation, smooth muscle cell relaxation, compression of the iliac veins due to increased uterine
size, slower venous flow, stasis, and venous valve incompetence. All this results in a situation of
venous hypertension, which can lead to the development of varicose veins, especially during the third
trimester of pregnancy [5–7]. Both oestrogen and progesterone play an important role in all these
changes in the cardiovascular system, and especially in CVD [8,9].
The roles of all these changes in the placenta have not yet been fully elucidated. We have previously
shown that lower extremity CVD during pregnancy is associated with some placental changes, such as
extracellular matrix remodelling or increased placental apoptosis and villous calcification, along with
increased expression of tissue hypoxia markers [10–12]. These mechanisms are also dysregulated at
the placental level in other important vascular diseases, such as preeclampsia and intrauterine foetal
growth restriction [13–15]. It should be highlighted how all these pathological conditions affect the
process of angiogenesis. Placental growth factor (PIGF) has an important role in angiogenesis, as well
as in the proper function of the placenta [16,17]. In women with CVD during pregnancy, overexpression
of vascular endothelial growth factor (VEGF) has been reported, explaining its role in the disease’s
pathogenesis [12]. Likewise, the VEGF receptors VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-2) play roles
in various vascular diseases, such as preeclampsia [18,19]. Interestingly, VEGF has been observed
to regulate, through Flt-1 and KDR signalling, the levels of sFlt-1 a soluble VEGF and PIGF receptor
overexpressed in such pregnancy vascular diseases, showing the importance of the balance of these
factors during pregnancy [20–22]. On the basis of the above, the aim of the present study is to examine
angiogenesis and lymphogenesis in the placental villi of women with CVD during pregnancy compared
with patients without CVD, by examining the gene and protein expression of CD31, podoplanin (D2-40),
Flt-1, and PIGF.
2. Results
2.1. More Vessels Positive for CD31 and D2-40 in the Placental Villi of Women with CVD
We studied specific markers of angiogenesis (CD31) and lymphangiogenesis (D2-40) in the placental
villi of women with CVD versus healthy controls (HCs), using RT-qPCR and immunohistochemistry.
CD31 gene expression was significantly higher in placental villi of women with CVD (CVD = 32.83
(30.66–37.59), HC = 30.71 (27.51–33.77), ** p = 0.0019, Figure 1A). The number of vessels with positive
CD31 protein expression was significantly higher in CVD than HC (CVD = 498.00 (324.00–703.00),
HC = 315.00 (275.00–578.00), *** p < 0.0001, Figure 1B). The images in Figure 1C,D show CD31 was
present in the capillary endothelium of placental villi of both study groups, with more intensity in the
CVD group (arrow).
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Figure 1. A–B. mRNA expression levels by RT-qPCR and positive vessels number for CD-31. C–D.
Images showing the immunostaining for CD-31 in the placental villi for CVD (C) and HC (D) by
immunohistochemistry. E–F. mRNA expression levels by RT-qPCR and positive vessels number for
D2-40. G–H. Images showing the immunostaining for D2-40 in the placental villi for CVD (G) and
HC (H) by immunohistochemistry. CVD = pregnancy-associated lower extremity chronic venous
disease. HC = healthy controls with no history of CVD. p < 0.05 (*), p < 0.01 (**), and p < 0.001 (***).
Arrow = positive protein expression.
Significantly higher D2-40 (podoplanin) gene expression was seen in placental villi of the CVD group
(CVD = 37.01 (33.95–38.05), HC = 35.53 (33.62–38.41), * p = 0.0243, Figure 1E). The number of vessels positive
for D2-40 protein expression was significantly higher in placental villi of the CVD group compared with
HC (CVD = 78.50 (51.00–98.00), HC = 52.00 (42.00–86.00), * p = 0.0104, Figure 1F). D2-40 was distributed
sinuously along placental villi, being more intense in the CVD group (Figure 1G,H, arrow).
2.2. Women with CVD Show Greater Expression of Flt-1 and PIGF in Placental Villi
Flt-1 gene expression was significantly higher in placental villi of CVD than HC (CVD = 29.59
(28.35–38.60), HC = 26.36 (24.45–29.46), *** p < 0.0001, Figure 2A). The CVD group had more positive
villi for Flt-1 (CVD = 167.00 (125.00–243.00), HC = 126.00 (104.00–196.00), ** p = 0.012, Figure 2B).
Flt-1 was distributed homogeneously in the extracellular matrix of placental villi of the study groups,
with more intense expression in CVD (Figure 2C,D, arrow).
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Figure 2. A–B. mRNA expression levels by RT-qPCR and positive vessels number for Flt-1. C–D.
Images showing the immunostaining for Flt-1 in the placental villi for CVD (C) and HC (D) by
immunohistochemistry. E–F. mRNA expression levels by RT-qPCR and positive vessels number for
placental growth factor (PIGF). G–H. Images showing the immunostaining for PIGF in the placental
villi for CVD (G) and HC (H) by immunohistochemistry. CVD = pregnancy-associated lower extremity
chronic venous disease. HC = healthy controls with no history of CVD. p < 0.05 (*), p < 0.01 (**),
and p < 0.001 (***). Arrow = positive protein expression.
PIGF gene expression was significantly greater in placental villi of women with CVD (CVD = 30.07
(26.96–32.80), HC = 28.27 (24.66–30.79), * p = 0.036, Figure 2E), and these women had more placental
villi positive for PIGF (CVD = 132.00 (102.00–203.00), HC = 113.00 (99.00–165.00), * p = 0.0224, Figure 2F).
PIGF was found in the syncytiotrophoblast, cytotrophoblast, and extracellular matrix of placental villi,
with more intensity in the CVD group (Figure 2G,H, arrow).
2.3. More Placental Villi with Periodic Acid of Schiff (PAS)-Positive Material in Women with CVD
PAS staining showed that the percentage of placentas with PAS-positive material in villi was
91.93% (n = 57) in the CVD group, while it was 51.92% (n = 27) in the HC group, (Figure 3A).
Placental villi in CVD showed greater staining with a more intense leucofuchsin reaction (Figure 3B,C).
The Pearson χ2 test showed a significance of *** p < 0.0001.
Figure 3. A. Percentage of positive periodic acid of Schiff (PAS) placental villi in CVD and HC.
B–C. Representative images of PAS in CVD (B) and HC (C). CVD = pregnancy-associated lower
extremity chronic venous disease. HC = healthy controls with no history of CVD. p < 0.001 (***).
Asterisk = positive reaction.
3. Discussion
Pregnancy causes haemodynamic and mechanical changes, triggering vascular complications
such as lower extremity CVD [23]. Our previous studies showed how impaired venous hypertension
and venous return resulting from CVD during pregnancy created an environment of cellular hypoxia
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with associated cell damage, producing extracellular matrix remodelling [10–12]. In the present study,
we saw an increase in the proangiogenic and lymphangiogenic markers CD31, D2-40, Flt-1, and PIGF
in placental villi of women with CVD during pregnancy.
CD31 is altered in placental vascular pathology [24,25]. In an arterial pathology such as
preeclampsia, CD31 immunoreactivity is lower in the placenta than in control pregnancies [24,26].
However, Li et al. [27] showed no significant differences in CD31 level in the placenta of women with
preeclampsia. In general, angiogenesis and lymphangiogenesis are modified in vascular pathology [28].
Our results show greater CD31 mRNA levels in placental villi of women with CVD, along with more
CD31-positive vessels. Podoplanin (D2-40) was also higher in these patients. Our results are consistent
with the results of Kandemir et al. [29], showing that podoplanin was increased in the placenta of
women with vascular disorders. It should be noted that podoplanin, a mucin-like transmembrane
protein, is a specific marker of lymphatic endothelium [30]. The human placenta does not have a mature
lymphatic system, but chorionic villous stromal cells express podoplanin [31]. Podoplanin-expressing
stromal cells can function as primitive lymphatic vessels [32]. Podoplanin plays a role in foetal
angiogenesis during placental development, and abnormal activity leads to pregnancy diseases
associated with defective angiogenesis [29,32,33]. Podoplanin expression in the human placenta has
been suggested as a response to hypoxic-ischaemic conditions [29]. Placental villi of women with
CVD have shown increased expression of hypoxia markers, such as hypoxia-inducible factor-1α [10].
This point would explain why placental villi of women with CVD show higher expression of CD31
and podoplanin, given the cell hypoxia described above.
Vascular abnormalities during pregnancy change angiogenic markers such as Flt-1 and PIGF [34].
These markers and their ratio are important in clinical monitoring of patients with preeclampsia,
and they are used on a regular basis [35–37]. The Flt-1/PIGF ratio is increasingly used in the study
of restricted intrauterine growth [38]. All these pathological events are associated with hypoxic
processes affecting placental vascularisation [19]. Placental blood supply is associated with abnormal
expression of VEGF and PIGF, and thus of Flt-1 [39]. The gene and protein expression of these markers
is abnormal in placental vascular diseases [40]. We also saw this abnormal profile of Flt-1 and PIGF in
placental villi, both of which were upregulated in the extracellular matrix. Placental villi of women
with CVD have shown an increased expression of VEGF [12], explaining how vascular compromise
resulting from CVD during pregnancy induces angiogenesis and lymphangiogenesis in placental villi.
The placentas of our women with CVD had more villi with PAS-positive material than the control
placentas. The accumulation of polysaccharides suggests these villi are not fully functional, though the
processes described aim to correct the situation created by CVD.
4. Material and Methods
4.1. Study Population
An observational, analytical, and prospective cohort study was conducted on 114 women in their
third trimester of pregnancy (32 weeks). Sixty-two were clinically diagnosed with CVD, with a median
age of 33 years (22–40) and median gestational age (weeks) of 40.5 (39–41.5). In parallel, 52 controls with
no history of CVD (HC) were studied, with a median age of 34 years (27–41) and median gestational age
(weeks) of 41 (39–42). This study was conducted according to the basic ethical principles of autonomy,
beneficence, non-maleficence, and distributive justice. The study was developed according to the
standards of Good Clinical Research Practice, the principles set forth in the last Declaration of Helsinki
(2013), and the Oviedo Convention (1997). Patients were informed of the details of the study, and each
provided signed consent. The project FIS-PI18/00912 was approved (March of 2017) by the Clinical
Research Ethics Committee of the Gómez-Ulla-UAH Defence Hospital (37/17).
Clinical history was picked up during the third-trimester visit, and a general physical exam was
carried out. Lower extremities were studied using Doppler ultrasound at 7.5 MHz (Portable M-Turbo
Doppler Ultrasound, SonoSite, Inc., Washington, USA). In this work, women over 18 years during
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the third trimester of pregnancy with clinical evidence of lower extremity CVD were included, with
clinical, etiological, anatomical, pathological (CEAP) C-classes ≥1 (C1 = 59.67% (n = 37), C2 = 33.87%
(n = 21), C3 = 6.45% (n = 4)). Examination of the venous system of the lower extremities of the study
patients was performed using a 7.5 MHz Eco-Doppler transducer (M-Turbo Eco-Doppler, SonoSite,
Inc.). A detailed examination (main saphenous axis from the inguinal region to the ankle and femoral
veins) was carried out with the woman standing and her leg in external rotation. Exclusion criteria were
defined by women with endocrine diseases as diabetes mellitus; high blood pressure (HBP); body mass
index (BMI) ≥ 25 kg/m2; unhealthy habits; active infectious diseases; autoimmune diseases; venous
malformations; kidney, heart, or lung failure; preeclampsia and/or haemolysis, elevated liver enzymes
and low platelets (HELLP) syndrome; intrauterine growth restriction by known causes; presence
of pathological lesions such as placental infarcts, avascular villi, delayed maturation, and chronic
inflammation affecting chorionic villi, along with the emergence of any of the previous exclusion
criteria any time before to delivery; as well as prior evidence of CVD.
4.2. Placental Tissue Samples
After delivery, placental biopsies were collected. To ensure that the samples included multiple
cotyledons, five placental pieces were obtained using a scalpel in all cases. Placental fragments
were put into two different sterile tubes—one including minimum essential medium (MEM) with 1%
antibiotic/antimycotic (both from ThermoFisher Scientific, Waltham, MA, USA) and another containing
RNAlater® solution (Ambion, Austin, TX, USA). In the laboratory, the samples were processed in
a sterile environment in a class II laminar flow hood (Telstar AV 30/70 Müller 220 V 50 MHz; Telstar SA
Group, Terrassa, Spain). Samples were kept in 1 mL of RNAlater® at –80◦C and preserved until
further processing for gene expression analysis. MEM samples were destined to histological and
immunodetection studies.
Samples within MEM were washed and rehydrated various times with antibiotic-free medium,
eliminating blood cells, then divided into fragments, and afterwards fixed in F13 (60% ethanol,
20% methanol, 7% polyethylene glycol, 13% distilled H2O), as shown in established protocols.
Following inclusion, paraffin blocks were made using molds. Posterior to paraffin’s solidification, an
HM 350 S rotation microtome (Thermo Fisher Scientific, MA, USA) was used to produce 5 µm thick
sections, which were taken to a hot water bath, collecting them on a glass slides, and treated with 10%
polylysine for better adhesion of the cuts.
4.3. Gene Expression Analysis Using RT-qPCR
RNA extraction was executed according to the guanidinium thiocyanate-phenol-chloroform
method described by Ortega et al. [41]. RT-qPCR was performed in a StepOnePlus™ System (Applied
Biosystems – Life Technologies, Waltham, MA, USA), with the standard curve method. The reaction
was carried out as follows: 5 µL of each sample in a 1:20 dilution in nuclease-free water was mixed
with 10 µL of DNase- and RNase-free water and then placed into a MicroAmp® 96-well plate (Applied
Biosystems – Life Techno logies) for a final reaction volume of 20 µL. All sequences were designed de
novo as follows in Table 1, using the Primer-BLAST [42].
Table 1. RT-qPCR primer sequences and temperature (Temp). PIGF, placental growth factor.
GENE SEQUENCE Fwd (5′→3′) SEQUENCE Rev (5′→3′) Temp
TBP TGCACAGGAGCCAAGAGTGAA CACATCACAGCTCCCCACCA 60 ◦C
CD-31 ACTGCACAGCCTTCAACAGA TTCTTCCATGGGGCAAG 60 ◦C
D2-40 TGACTCCAGGAACCAGCGAAG GCGAATGCCTGTTACACTGTTGA 50 ◦C
Flt-1 TCAGCTACTGGGACACCGG CCTGAACTAGATCCTGTGAGAAGCA 60 ◦C
PIGF CAGAGGTGGAAGTGGTACCCTTCC CGGATCTTTAGGAGCTGCATGGTGAC 58 ◦C
4.4. Protein Expression Analysis by Immunohistochemistry
Detection of the antigen–antibody reaction was achieved by using the avidin–biotin complex
(ABC) method, with peroxidase or alkaline phosphatase as chromogens. The whole procedure was
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described meticulously by Ortega et al. [43]. Firstly, samples were incubated at 4 ◦C overnight in
a dilution composed by primary antibody, BSA 3%, and PBS, as detailed in Table 2A. Afterwards,
samples were incubated in biotin-conjugated secondary antibody, and diluted in PBS during 1.5 h
at room temperature (Table 2B). Finally, the avidin–peroxidase conjugate ExtrAvidin®–Peroxidase
(Sigma-Aldrich, St. Louis, MO, USA) was applied for 60 min at room temperature (1:200 dilution
in PBS), using the chromogenic substrate diaminobenzidine (Kit DAB, SK-4100, Vector Laboratories,
Burlingame, CA, USA) to reveal, which was prepared just before exposure (5 mL of distilled water,
two drops of buffer, four drops of DAB, two drops of hydrogen peroxide), eventually resulting
in a brown stain. In all immunohistochemical studies, sections of the same tissue were used as
a negative control, in which primary antibody incubation was substituted with incubation in blocking
solution (PBS).
Table 2. Antibodies (A. primary, B. secondary) used in the immunohistochemical studies performed
with dilutions and specifications protocols.
A
Antigen Species Dilution Provider Protocol specifications
CD-31 Mouse monoclonal 1:100 P-8590 (Sigma-Aldrich)
D2-40 Mouse monoclonal 1:100 M3619 (Agilent, Dako)
Flt-1 Mouse monoclonal 1:500 sc-271789 (Santa cruzbiotechnology)
Citrate tampon in heat
(pH =6)
PlGF Rabbit polyclonal 1:250 ab230516 (Abcam)




Antigen Species Dilution Provider Protocol specifications
IgG (Mouse) Goat polyclonal 1:300 Sigma-Aldrich(F2012/045K6072 )
IgG (Rabbit) Mouse polyclonal 1:1000 Sigma-Aldrich (RG-96/B5283)
4.5. Periodic Acid of Schiff (PAS) Staining
PAS staining is one of the most common methods used in histology to show the presence of
aldehyde groups derived from carbohydrate oxidation. We used a PAS staining kit (cat. #1016460001)
from MERCK (Darmstadt, Germany). Once the sections were deparaffinized and rehydrated, they were
rinsed with distilled water. The histological material was first treated with periodic acid for 5 min to
oxidize 1,2-glycols to aldehyde groups. To obtain a high and suitable staining specificity, the tissue
was treated with sulfite water (3 × 2 min) after the reaction with periodic acid. Sulfite water was
prepared by first mixing 10 mL of 10% sodium bisulfite solution and 10 mL of 1 mol/L hydrochloric acid,
and then this solution was mixed with 200 mL of tap water. By adding the Schiff reagent (leucofuchsin)
in the second step (15 min), aldehydes reacted, producing an intense red colour. To obtain a bright and
contrasting pattern of PAS-positive structures, a haematoxylin solution modified according to Gill II
was used. Deparaffinization, rehydration, and mounting processes were as usual [44].
4.6. Statistical Analysis and Interpretation of Results
The statistical analysis was carried out using the program GraphPad Prism® 6.0.
The Mann–Whitney U and Pearson χ2 tests were studied in this work. The obtained data are
expressed as the median with interquartile range (IQR) and significance was established at p < 0.05 (*),
p < 0.01 (**), and p < 0.001 (***). Five sections and ten fields per section were randomly analyzed for
each patient classified in their established groups. Patients were considered positive when the marked
average area in the analysed sample was ≥5% of the total, following the pathology protocol. The slides
were examined under a Zeiss Axiophot optical microscope (Carl Zeiss, Germany).
5. Conclusions
Our results show for the first time how, in pregnant women with CVD, normal vascularization of
villi is affected in placental villi. These villi have upregulated angiogenesis and lymphangiogenesis
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markers, related to an increase in vascularisation. It is necessary to know how these events can
compromise the function of placental villi and, therefore, the maternal–foetal gas exchange.
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